Queen's Award Received in 2021 ISO 9001 Certified Delivered over 1,000,000 bio-reagents to life science researchers Trusted by Life Science Communities
Cart summary

You have no items in your shopping cart.

NIBR-0213

SKU: orb1304983

Description

NIBR-0213 is a potent, competitive, and selective S1P1 receptor antagonist, demonstrating IC50 values of 2.0 nM (human) and 2.3 nM (rat) in GTPγS binding assays. It shows efficacy in the experimental autoimmune encephalomyelitis (EAE) model, supporting its use in researching multiple sclerosis and other autoimmune disorders.

Research Area

Pharmacology & Drug Discovery

Images & Validation

Key Properties

CAS Number1233332-14-3
MW464.98
Purity98.36% (May vary between batches)
FormulaC27H29ClN2O3
SMILESCC=1C=C(C=C(C)C1C(N[C@H](C(O)=O)C)=O)C2=CC(N[C@H](C)C3=CC(C)=C(Cl)C=C3)=CC=C2
TargetLPL Receptor
SolubilityDMSO:55 mg/mL (118.28 mM)

Bioactivity

Target IC50
S1P1:2.0 nM(GTPγ35S,human)|S1P1:2.3 nM(GTPγ35S,rat)|S1P1:2.5 nM(Ca2+ mobilization)|S1P1:8.5 nM(GTPγ35S,mouse)
In Vivo
METHODS: NIBR-0213 (30, 100, 300 mg/kg, oral, once daily, for two weeks) was used to treat the rat adjuvant-induced arthritis (AiA) model to explore the functional/pathophysiological consequences of the disruption of S1P1-dependent vascular permeability homeostasis caused by its competitive antagonism. RESULTS An effective oral dose of 30 mg/kg BID was tolerated without signs of dyspnea but induced dose-dependent acute vascular lung leak and pleural effusion, which completely resolved within 3-4 days; at a supramaximal oral dose of 300 mg/kg QD, NIBR-0213 impaired lung function (increased respiratory rate and decreased tidal volume) within the first 24 hours; NIBR-0213 at doses of 30, 100, and 300 mg/kg induced moderate lung changes after two weeks, characterized by alveolar wall thickening, macrophage accumulation, fibrosis, microhemorrhage, edema, and necrosis.
In Vitro
In the Ca2+ assay, NIBR-0213 showed inhibitory activity against hS1P1 with an IC50 of 2.5 nM, but was inactive against S1P2, S1P3, and S1P4 (IC50 > 10 μM); in the GTPγ35S assay, NIBR-0213 showed potent and comparable potency against human and rat S1P1 (IC50 of 2.0 nM and 2.3 nM, respectively), while the IC50 for mouse S1P1 was slightly lower at 8.5 nM.

Storage & Handling

Storage-20°C
Expiration Date12 months from date of receipt.
DisclaimerFor research use only

Alternative Names

autoimmune, encephalomyelitis, Inhibitor, inhibit, LPL Receptor, LPLReceptor, NIBR 0213, NIBR0213, NIBR-0213, Lysophospholipid Receptor, S1PR1, S1P1
Quality Guarantee

Quality Guarantee

Explore bioreagents carefree to elevate your research. All our products are rigorously tested for performance. If a product does not perform as described on its datasheet, our scientific support team will provide expert troubleshooting, a prompt replacement, or a refund. For full details, please see our Terms & Conditions and Buying Guide. Contact us at [email protected].

Key Properties

No computed properties available.

Documents Download

Datasheet
Product Information
Download

Request a Document

Protocol Information

NIBR-0213 (orb1304983)

  • Star
  • Star
  • Star
  • Star
  • Star
  • 0.0
Based on 0 reviews

Participating in our Biorbyt product reviews program enables you to support fellow scientists by sharing your firsthand experience with our products.

Login to Submit a Review

No reviews yet

Step 1: Enter information below

(Recommended: An additional animal making an allowance for loss during the experiment)

Step 2: Enter the in vivo formulation

(This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO +
%+
% Tween 80 +
%

Available Sizes

Select a size below

1 mg
$ 80.00
5 mg
$ 120.00
1 ml x 10 mM (in DMSO)
$ 140.00
10 mg
$ 160.00
25 mg
$ 270.00
DispatchUsually dispatched within 3-5 working days
Bulk Enquiry